Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELITE PHARMACEUTICALS INC /NV/ELTP · Entity 5936 | Director · CEO, President · 10% owner | March 29, 2024 | April 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELITE PHARMACEUTICALS INC /NV/
Report date March 29, 2024 · Filed April 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,649,250 |
Reported balance
After 2024-03-29 transaction · row 1
1 source rowRow 1 · 2024-03-29 · Grant · Acquired 49,534,368 · Balance 216,649,250 F1: Shares issued in settlement of compensation owed to the Reporting Person pursuant to his Employment Agreement with the issuer, dated August 1, 2013, as amended. |
| Common StockSEC Table I · non-derivative | Indirectby IRA | 2,700,000 |
Reported balance
Holding disclosure · report date 2024-03-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,700,000 |
| Common StockSEC Table I · non-derivative | Indirectby Kristine Hakim | 2,223,147 |
Reported balance
Holding disclosure · report date 2024-03-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,223,147 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued in settlement of compensation owed to the Reporting Person pursuant to his Employment Agreement with the issuer, dated August 1, 2013, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2024 Filed Apr 2, 2024 20:58 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 49,534,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-012832 · ownership.xml · nonDerivative · entry 1 Hakim Nasrat A · CIK 0001583742 · Director · CEO, President · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,649,250 F1 · shares: Shares issued in settlement of compensation owed to the Reporting Person pursuant to his Employment Agreement with the issuer, dated August 1, 2013, as amended. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 19:21 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 2,223,147 | $0.07 | $153,397.14 |
DisclosureSEC source: 0001583742-23-000001 · primary_doc.xml · nonDerivative · entry 1 Hakim Nasrat A · CIK 0001583742 · Director · CEO, President · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Kristine Hakim Disclosed balance after: 2,223,147 F1 · shares: Shares issued in lieu of cash compensation for Pharmacovigilance and Medical Affairs consulting work during 2018-2022. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 17:29 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | ConversionSeries J Convertible Preferred Shares · Derivative | 24.0344 | $0.00 | $0.00 |
DisclosureSEC source: 0001583742-20-000002 · primary_doc.xml · derivative · entry 3 Hakim Nasrat A · CIK 0001583742 · Director · CEO & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 158,017,321 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred shares are convertible into shares of common stock at a rate of 6,576,878.18 shares of common stock for each whole share of preferred stock, effectively $0.1521 per share of common stock. F1 · price: The preferred shares are convertible into shares of common stock at a rate of 6,576,878.18 shares of common stock for each whole share of preferred stock, effectively $0.1521 per share of common stock. F2 · derivative.exercise_date: Shareholder Approval was obtained on June 23, 2020 for an increase in the number of authorized shares of common stock to permit full conversion of the preferred stock. F3 · derivative.expiration_date: None Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 17:29 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | ConversionCommon Stock | 158,017,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001583742-20-000002 · primary_doc.xml · nonDerivative · entry 1 Hakim Nasrat A · CIK 0001583742 · Director · CEO & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,114,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2017 Filed May 3, 2017 22:17 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | OtherWarrants · Derivative | 79,008,661 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001583742-17-000002 · primary_doc.xml · derivative · entry 4 Hakim Nasrat A · CIK 0001583742 · Director · CEO & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,008,661 Underlying: Common Stock · 79,008,661 shares Expires 2027-04-28 F1 · kind: The common shares were returned to the company in exchange for the Series J Convertible Preferred Shares and warrants issued by the company. F3 · derivative.exercise_date: The date that Shareholder Approval is obtained for an increase in the number of authorized shares of common stock to permit full conversion of the preferred stock and exercise of the warrants. Read SEC document |
| April 28, 2017 Filed May 3, 2017 22:17 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | OtherSeries J Convertible Preferred Shares · Derivative | 24.0344 | $1,000,000.00 Strike: $1,000,000.00 | $24,034,400.00 |
DisclosureSEC source: 0001583742-17-000002 · primary_doc.xml · derivative · entry 3 Hakim Nasrat A · CIK 0001583742 · Director · CEO & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24.0344 Underlying: Common Stock · 158,017,321 shares Expires not disclosed F1 · security: The common shares were returned to the company in exchange for the Series J Convertible Preferred Shares and warrants issued by the company. F1 · kind: The common shares were returned to the company in exchange for the Series J Convertible Preferred Shares and warrants issued by the company. F2 · shares: The preferred shares are convertible into shares of common stock at a rate of 6,576,878.18 shares of common stock for each whole share of preferred stock. F3 · derivative.exercise_date: The date that Shareholder Approval is obtained for an increase in the number of authorized shares of common stock to permit full conversion of the preferred stock and exercise of the warrants. F4 · derivative.expiration_date: None. F2 · balance_after: The preferred shares are convertible into shares of common stock at a rate of 6,576,878.18 shares of common stock for each whole share of preferred stock. Read SEC document |
| April 28, 2017 Filed May 3, 2017 22:17 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | OtherCommon Stock | 158,017,321 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001583742-17-000002 · primary_doc.xml · nonDerivative · entry 1 Hakim Nasrat A · CIK 0001583742 · Director · CEO & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,097,561 F1 · kind: The common shares were returned to the company in exchange for the Series J Convertible Preferred Shares and warrants issued by the company. F1 · shares: The common shares were returned to the company in exchange for the Series J Convertible Preferred Shares and warrants issued by the company. F1 · price: The common shares were returned to the company in exchange for the Series J Convertible Preferred Shares and warrants issued by the company. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:09 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 2,216,992 | $0.23 | $499,931.70 |
DisclosureSEC source: 0001053369-17-000001 · primary_doc.xml · nonDerivative · entry 1 Hakim Nasrat A · CIK 0001583742 · Director · CEO & President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,143,785 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.